Compare Recursion Pharmaceuticals Inc (RXRX) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B), while Consumer Discretionary Select Sector SPDR Fund trades at $119.22. The key difference: Consumer Discretionary Select Sector SPDR Fund is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | XLY | |
|---|---|---|
Market Cap | $1.78B | — |
Sector | Health | — |
52-Week High | $6.79 | $124.52 |
52-Week Low | $2.84 | $105.64 |
Enterprise Value | $1.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
XLY trades at $119.86, up 1.47% with strong bullish technical momentum indicated by moving averages. Analyst consensus is unanimously positive with 100% buy ratings. The consumer discretionary ETF shows resilience amid economic uncertainty, with recent news highlighting its potential as a 'sleeper ETF' for Q3 2026. Technical indicators show overbought conditions on short-term RSI but strong trend momentum on ADX readings.
XLY presents a bullish case with strong technical momentum and unanimous analyst support, though current RSI levels suggest potential near-term consolidation. The ETF's performance hinges on consumer discretionary spending trends amid evolving inflation dynamics. Key risks include consumer confidence erosion and broader economic pressures affecting discretionary purchases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
